Search
vinorelbine (Navelbine)
Indications:
- lymphoma
- metastatic breast cancer
- non-small cell lung cancer, alone or in combination with cisplatin
- small cell carcinoma [3]
- uterine cancer
- Kaposi's sarcoma [3]
Dosage:
1) 15-30 mg/m2 IV weekly
2) dosage adjustment for bilirubin > 3.0 mg/dL: 7.5 mg/m2
3) dilute prior to administration
4) ensure IV access
Injection: 10 mg/mL (1 mL, 5 mL).
Pharmacokinetics:
1) widely distributed
2) metabolized by the liver
3) eliminated in the urine & feces
4) elimination 1/2life approximately 23 hours
Adverse effects:
1) not common (1-10%)
- chest pain, decreased deep tendon reflexes, tumor pain, jaw pain, paresthesia, phlebitis at site of infusion, nausea/vomiting, constipation, abnormal liver function tests, dyspnea (acute & reversible), hypoxemia, interstitial pulmonary infiltrates, SIADH, fatigue, hemorrhagic cystitis
2) uncommon (< 1%)
- alopecia, thrombocytopenia, myocardial infarction
3) other
- myelosuppression
- leukopenia, neutropenia, anemia
- thrombocytopenia (uncommon)
- nadir 7-8 days
- recovery 15-17 days
- irritant/extravasation
- peripheral neuropathy
- ileus
- urinary retention
- ototoxicity
Drug interactions:
1) aminoglycosides given within 3-5 days can increase the risk of ototoxicity
2) mitomycin-C in combination may result in acute pulmonary syndrome which may occur up to 2 weeks after last dose of mitomycin-C
Mechanism of action:
1) vinca alkaloid
2) inhibits microtubule formation in the mitotic spindle arresting cell division
Related
intravenous (IV) extravasation
General
antimitotic agent; mitotic inhibitor (antineoplastic agent)
vinca alkaloid
Properties
MISC-INFO: elimination route KIDNEY
pregnancy-category D
1/2life 23 HOURS
Database Correlations
PUBCHEM correlations
References
- Drug Information & Medication Formulary, Veterans Affairs,
Central California Health Care System, 1st ed., Ravnan et al
eds, 1998
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Deprecated Reference